WO2013043558A1 - Compositions et méthodes de traitement du cancer - Google Patents
Compositions et méthodes de traitement du cancer Download PDFInfo
- Publication number
- WO2013043558A1 WO2013043558A1 PCT/US2012/055847 US2012055847W WO2013043558A1 WO 2013043558 A1 WO2013043558 A1 WO 2013043558A1 US 2012055847 W US2012055847 W US 2012055847W WO 2013043558 A1 WO2013043558 A1 WO 2013043558A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- formula
- compounds
- present
- Prior art date
Links
- BPXINCHFOLVVSG-UHFFFAOYSA-N Clc1c(cccc2)c2nc2c1cccc2 Chemical compound Clc1c(cccc2)c2nc2c1cccc2 BPXINCHFOLVVSG-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N c(cc1)ccc1Oc1ccccc1 Chemical compound c(cc1)ccc1Oc1ccccc1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
Definitions
- Intercalation is one of several modes by which drugs interact with DNA wherein a planar portion of the drug is inserted in between adjacent stacked base pairs of a double stranded DNA.
- the intercalation process results in helix extension and unwinding of the DNA.
- antitumor agents include antitumor agents, actinomycin D, adriamycin and daunomycin, as well as several drugs for treatment of parasitic disease including ethidium bromide, quinacrine, chloroquine and miracil D.
- US Patent No. 2,441,665 discloses a class of alkylene diamine derivatives which are valuable as antimalarial agents.
- US Patent No. 2,113,357 discloses substituted amino-acridine derivatives useful in treating blood parasites.
- DNA intercalating ligands have also been shown to be useful in targeting alkylating agents to DNA by attachment of the intercalating ligand to the alkylating agent
- the present invention features a compound of Formula I, or a pharmaceutically acceptable salt and solvate thereof,
- dashed lines represent bonds that are independently present or absent; and each R is independently an amide, amino, azido, nitro, hydroxyl, hydroxymethyl, carboxyl, cyano, sulfinyl, aryl, heteroaryl, alkenyl, alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycle, spirocycle, alkoxy, or halo group.
- compositions and methods of inhibiting cancer cell growth and treating cancer in a subject using a compound of the invention are also provided.
- the present invention features anti-cancer compounds, pharmaceutical compositions and methods for decreasing tumor cell proliferation, increasing survival, and treating cancer.
- bis-acridine or bis- quinoline intercalators having a modified bis (4- aminophenyl) ether tether have now been developed to improve activity, selectivity, solubility and bioavailability of the antitumor compound.
- Compounds of the invention find application in decreasing cancer cell proliferation thereby making them useful in the treatment of cancer.
- dashed lines represent bonds (A-E) that are independently present or absent; and R is a group that improves one or more of the pharmacological properties of the drug, e.g., solubility, permeability, bioavailability, stability, pKa, lipophilicity, blood brain barrier penetration, excretion, absorption, distribution, metabolism, transport, clearance, half-life, etc.
- R is an ionizable group, polar group or group capable of participating in Hi- bonding.
- each R is independently an amide (-CONH 2 ) , amino (-NH 2 ) , azido (-N 3 ) , nitro (-N0 2 ) , hydroxyl (-OH) , hydroxymethyl (-CH 2 OH) , carboxyl (-C0 2 H) , cyano (-C ⁇ N) , sulfinyl (-SO) , aryl, heteroaryl, alkenyl, alkyl, alkylene, cycloalkyl, cycloalkenyl, heterocycle, spirocycle, alkoxy, or halo (-Br, -F, -CI, -I) group.
- aryl refers to an optionally substituted benzene ring or to an optionally substituted fused benzene ring system, for example anthracene, phenanthrene, or naphthalene ring systems. Multiple degrees of substitution are included within the present definition. Examples of “aryl” groups include, but are not limited to, phenyl, 2-naphthyl, 1-naphthyl, and the like, as well as substituted derivatives thereof.
- heteroaryl refers to an optionally substituted monocyclic five to seven membered aromatic ring, or to an optionally substituted fused bicyclic aromatic ring system comprising two of such aromatic rings.
- These heteroaryl rings contain one or more heteroatoms such as nitrogen, sulfur, and/or oxygen atoms, where N-oxides, sulfur oxides, and dioxides are permissible heteroatom substitutions. Multiple degrees of substitution are included within the present definition.
- heteroaryl groups used herein include, but should not be limited to, furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, indazole, benzimidizolyl, imidazopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, and the like, as well as substituted versions thereof.
- alkenyl refers to a straight or branched chain aliphatic hydrocarbon containing one or more carbon-to-carbon double bonds that may be optionally substituted, with multiple degrees of substitution included within the present invention. Examples include, but are not limited to, vinyl, allyl, and the like, as well as substituted versions thereof.
- alkyl refers to a straight or branched chain hydrocarbon, preferably having from one to twelve carbon atoms, which may be optionally substituted, with multiple degrees of substitution included within the present invention.
- alkyl as used herein include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, isopentyl, n-pentyl, and the like, as well as substituted versions thereof.
- alkylene refers to a straight or branched chain divalent hydrocarbon radical, preferably having from one to ten carbon atoms. Alkylene groups as defined herein may optionally be substituted, with multiple degrees of substitution included within the present invention. Examples of “alkylene” as used herein include, but are not limited to, methylene, ethylene, n- propylene, n-butylene, and the like, as well as substituted versions thereof.
- cycloalkyl refers to an optionally substituted non-aromatic cyclic hydrocarbon ring, which optionally includes an alkylene linker through which the cycloalkyl may be attached, with multiple degrees of substitution included within the present invention.
- exemplary "cycloalkyl” groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, as well as substituted versions thereof.
- cycloalkyl includes an optionally substituted fused polycyclic hydrocarbon saturated ring and aromatic ring system, namely polycyclic hydrocarbons with less than maximum number of non- cumulative double bonds, for example where a saturated hydrocarbon ring (such as a cyclopentyl ring) is fused with an aromatic ring (herein “aryl,” such as a benzene ring) to form, for example, groups such as indane.
- aryl such as a benzene ring
- cycloalkenyl refers to an optionally substituted non-aromatic cyclic hydrocarbon ring containing one or more carbon-to-carbon double bonds which optionally includes an alkylene linker through which the cycloalkenyl may be attached, with multiple degrees of substitution included within the present invention.
- exemplary "cycloalkenyl” groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like, as well as substituted versions thereof.
- heterocycle refers to an optionally substituted mono- or polycyclic ring system optionally containing one or more degrees of unsaturation and also containing one or more heteroatoms.
- Preferred heteroatoms include N, O, and/or S, including N-oxides, sulfur oxides, and dioxides.
- the ring is three to twelve-membered and is either fully saturated or has one or more degrees of unsaturation. Multiple degrees of substitution are included within the present definition.
- Such rings may be optionally fused to one or more of another "heterocyclic" ring(s) or cycloalkyl ring(s).
- heterocyclic groups include, but are not limited to, tetrahydrofuran, pyran, 1,4-dioxane, 1,3- dioxane, piperidine, pyrrolidine, morpholine, tetrahydrothiopyran, and tetrahydrothiophene.
- spirocyclyl refers to an alkylene diradical, each end of which is attached to the same carbon atom of the parent molecular moiety forming a bicyclic moiety.
- alkoxy refers to the group -0R a , where R a is alkyl as defined above.
- the phrase "optionally substituted” or variations thereof denote an optional substitution, including multiple degrees of substitution, with one or more substitutent group.
- exemplary optional substituent groups include acyl; alkyl; alkenyl; alkynyl; alkylsulfonyl; alkoxy; alkoxycarbonyl; cyano; halogen; haloalkyl; hydroxy; nitro; aryl, which may be further substituted with acyl, alkoxy, alkyl, alkenyl, alkynyl, alkylsulfonyl, cyano, halogen, haloalkyl, hydroxy, or nitro .
- a compound of Formula I can include one or more of bonds A-E, and hence one to four additional carbons, with the appropriate valencies.
- bonds B, C, and/or D are only present when one or both of bonds A or E are present.
- compounds of the invention can include, bond A, bonds A-B, bonds A-C, bonds A-D, bonds A-E, bonds B-E, bonds C-E, bonds D-E, bond D, or bonds A-B and D-E.
- a compound of the invention includes bond E.
- a compound of the invention includes bonds A-E.
- bonds A-D or B-E can form a five- membered ring.
- Exemplary acridine and quinoline molecules of the instant compound include, but are not limited to,
- the one or more rings of acridine and quinoline molecules can be modified with one or more heteroatoms to produce modified bisintercalators.
- Compounds of Formula I can be prepared and purified using any other suitable methodology routinely practiced in the art (see, Examples 1 and 2), and be analyzed for their pharmacological properties by routine methodologies. For example, kinetic solubility can be measured using a direct UV absorbance method or thermodynamic solubility can be measured. In addition, stability in gastrointestinal fluids can be determined by conventional methods (Asafu-Adj aye, et al. (2007) J. Pharm. Biomed. Anal. 43:1854-1859), e.g., 1 hour in simulated gastric fluid (pH 1.2, pepsin) at 37 °C and/or 3 hours in simulated intestinal fluid (pH 6.8, pancreatin) .
- PAMPA Parallel Artificial Membrane Permeability Assay
- BBB blood-brain barrier
- R of Formula I is a tetrazole or CO 2 H
- an internal salt can be prepared.
- pharmaceutically acceptable salts of the present invention can be prepared by conventional methods. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Salts of the compounds of the present invention may include acid addition salts. In general, the salts are formed from pharmaceutically acceptable inorganic and organic acids, or bases, as well as quaternary ammonium salts.
- suitable acid salts include maleic, hydrochloric, hydrobromic, sulphuric, phosphoric, nitric, perchloric, fumic, acetic, propionic, succinic, glycolic, formic, lactic, aleic, tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methansulfonic (mesylate) , naphthaliene-2-sulfonic, benzenesulfonic, hydroxynaphthoic, hydroiodic, malic, teroic, tannic, and the like.
- Other representative salts include acetate, benzenesulfonate, benzoate, besylate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, clavulanate, citrate, dihydrochloride, editate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N- methylglucamine, oxalate, pamoate
- Suitable basic salts include benzathine, sodium, lysine, lithium, potassium, magnesium, aluminum, calcium, zinc, ⁇ , ⁇ '- dibenzylethylenediamine, chloroprocaine, chlorine, diethanolamine, ethylenediamine, N-methylglucamine, and procaine salts.
- solvate refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of Formula I, or a salt thereof) and a solvent.
- solvents for the purpose of the invention, should not interfere with the biological activity of the solute.
- suitable solvents include, but are not limited to water, methanol, ethanol, and acetic acid.
- the solvent used is a pharmaceutically acceptable solvent.
- suitable pharmaceutically acceptable solvents include water, ethanol, and acetic acid.
- the DNA binding activity and efficacy of the compounds of this invention can be demonstrated using any convention method.
- thermal denaturation studies can be performed on calf thymus DNA (see, e.g., Fiel, et al . (1979) Nucleic Acids Res. 6 ( 9) : 3093-118 ; Nakaike, et al. (1992) Jpn. J. Cancer Res. 83 (4) : 402-9; Fairley, et al. (1993) J. Med. Chem. 36 (12) : 1746-53) .
- the compounds can be analyzed for their ability to exhibit cytotoxicity in suitable cell line or animal models of cancer.
- the murine leukemia cell line, L1210 is used in in vitro assays (Jaycox, et al . (1987) J. Heterocyclic. Chem. 24:1405-1408), as well as in in vivo assays, wherein CD2F1 mice receive L1210 leukemia cells by intraperitoneal injection (Edanami, et al. (1984) Cancer Chemother Pharmacol. 13(l):22-6; Douzono, et al. (1995) Jpn. J. Cancer Res. 86 ( 3 ) : 315-21 ) .
- the human mammary carcinoma MX-1 xenograft model is routinely used in the preclinical analysis of anti-tumor compounds in the treatment of breast cancer (Zhao, et al. (2008) Bioconjug Chem. 19 (4 ): 849-59; Wada, et al. (2007) Anticancer Res. 27:1431-5; Donawho, et al . (2007) Clin Cancer Res. 13:2728-37).
- NU/NU Swiss (nude) mice receive an intrarenal inoculation of MX-1 cells prior to or after treatment with the test compound.
- the human lung LX-1 xenograft model wherein nude mice receive an intrarenal inoculation of LX-1 tumor cells, is also routinely used in the preclinical analysis of anti-tumor compounds (Masuda, et al. (2006) J. Antibiot . (Tokyo) 59 ( 4 ) : 209-14 ) .
- Similar models exist for the analysis of anti-tumor activity in prostate cancer e.g., the TRAMP model, wherein transgenic mice develop spontaneous prostate cancer
- skin cancer e.g., the Mouse B16 Melanoma model
- ovarian cancer mouse ovarian carcinoma xenograft model; Davis, et al .
- kidney cancer e.g., the murine renal cell carcinoma model (RENCA model)
- RENCA model murine renal cell carcinoma model
- any suitable rodent or primate model can be used in the analysis of anti-tumor activity of the instant compounds.
- survival and/or tumor size is measured and the results are expressed as the measurement made in the treated group divided by the measurement made in the vehicle treated control group. Results of this analysis are expected to demonstrate that tumor size is decreased and or survival is increased in animals receiving treatment with a compound of the present invention .
- the compounds of the present invention find use in the treatment of cancer.
- the compounds of the present invention are contemplated as being more effective inhibitors of cancer cells than the anti-tumor bis-intercalators disclosed in the prior art because of their improved pharmacological properties.
- compounds of the present invention will be useful in treating subjects suffering from cancer, such as leukemia, colon cancer, glioma (including astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroectodermal tumors) , breast cancer, kidney cancer, lung cancer and the like.
- cancer such as leukemia, colon cancer, glioma (including astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroectodermal tumors)
- breast cancer such as leukemia, colon cancer, glioma (including astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroecto
- the present invention also provides methods for treating cancer, wherein an effective amount of a compound of the present invention is administered to the subject in need of treatment so that growth of the cancer cells is inhibited or decreased and the signs or symptoms of the cancer are delayed, ameliorated, decreased or reversed.
- treatment refers to both therapeutic treatment and prophylactic or preventative measures.
- those in need of treatment include those already with the disorder as well as those prone to have the disorder (e.g., by genetic predisposition or exposure to carcinogenic agents) .
- Subjects who can be treated in accordance with the present invention include mammals, such as humans, domestic and farm animals, and zoo, sports, or pet animals, e.g., dogs, horses, cats, cows, etc.
- mammals such as humans, domestic and farm animals, and zoo, sports, or pet animals, e.g., dogs, horses, cats, cows, etc.
- the mammal herein is human.
- the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought, for instance, by a researcher or clinician.
- effective amounts of a compound of Formula I, as well as salts or solvates thereof may be administered as the raw chemical or optionally presented as a pharmaceutical composition.
- the invention further provides pharmaceutical compositions (also referred to herein as "pharmaceutical formulations") that include effective amounts of compounds of the Formula I, or salts or solvates thereof, and one or more pharmaceutically acceptable excipients (including carriers and/or diluents) .
- the carrier (s), diluent (s) or excipient(s) must be acceptable, in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient of the pharmaceutical composition.
- a compound of the Formula I, or a salt or solvate thereof is admixed with one or more pharmaceutically acceptable carriers, diluents or excipients .
- compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
- a unit may contain, as a non-limiting example, 0.5 mg to 1 g of a compound of the Formula I, depending on the compound, the condition being treated, the route of administration, and the age, weight, and condition of the patient.
- Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
- Such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy art .
- compositions may be adapted for administration by any appropriate route, for example by an oral (including buccal or sublingual) , rectal, topical (including buccal, sublingual or transdermal) , vaginal, parenteral (including subcutaneous, intramuscular, intravenous .or intradermal), by implantation, by intracavitary or intravesical instillation, intraocular, intraarterial, or intralesional route, or by application to mucous membranes, such as, that of the nose, throat, and/or bronchial tubes (i.e., inhalation).
- Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier (s) or excipient (s) .
- compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions, each with aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
- the active drug component can be combined with an oral, nontoxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
- powders are prepared by comminuting the compound to a suitable fine size and mixing with an appropriate pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavorings, preservatives, dispersing agents, and coloring agents can also be present.
- Capsules are made by preparing a powder, liquid, or suspension mixture and encapsulating with gelatin or some other appropriate shell material.
- Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to the mixture before the encapsulation.
- a disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
- suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture.
- binders examples include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- Lubricants useful in these dosage forms include, for example, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant , and pressing into tablets.
- a powder mixture may be prepared by mixing the compound, suitably comminuted, with a diluent or base as described above.
- Optional ingredients include binders such as carboxymethylcellulose, aliginates, gelatins, or polyvinyl pyrrolidone, solution retardants such as paraffin, resorption accelerators such as a quaternary salt, and/or absorption agents such as bentonite, kaolin, or dicalcium phosphate.
- the powder mixture can be wet-granulated with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials, and forcing through a screen.
- a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials
- the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
- the granules can be lubricated to prevent sticking to the tablet-forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
- the lubricated mixture is then compressed into tablets.
- the compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
- a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material, and
- Oral fluids such as solutions, syrups, and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
- Syrups can be prepared, for example, by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
- Suspensions can be formulated generally by dispersing the compound in a non-toxic vehicle.
- Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives; flavor additives such as peppermint oil, or natural sweeteners, saccharin, or other artificial sweeteners; and the like can also be added.
- dosage unit formulations for oral administration can be microencapsulated.
- the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
- the compounds may also be coupled with soluble polymers as targetable drug carriers.
- soluble polymers can include polyvinylpyrrolidone (PVP) , pyran copolymer, polyhydroxypropylmethacrylamide-phenol , polyhydroxyethyl- aspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
- PVP polyvinylpyrrolidone
- pyran copolymer polyhydroxypropylmethacrylamide-phenol
- polyhydroxyethyl- aspartamidephenol polyhydroxyethyl- aspartamidephenol
- polyethyleneoxidepolylysine substituted with palmitoyl residues PVP
- the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug; for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans , polycyanoacrylates , and cross-linked or amphipathic block copolymers of hydrogels.
- biodegradable polymers useful in achieving controlled release of a drug
- compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
- the active ingredient may be delivered from the patch by iontophoresis.
- compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.
- the formulations may be applied as a topical ointment or cream.
- the active ingredient When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base .
- compositions adapted for topical administrations to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.
- compositions adapted for topical administration in the mouth include lozenges, pastilles, and mouthwashes.
- compositions adapted for nasal administration where the carrier is a solid, include a coarse powder having a particle size for example in the range 20 to 500 microns. The powder is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.
- Fine particle dusts or mists which may be generated by means of various types of metered dose pressurized aerosols, nebulizers, or insufflators .
- compositions adapted for rectal administration may be presented as suppositories or as enemas .
- compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.
- compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants , buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi- dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
- formulations may include other agents conventional in the art having regard to the type of formulation in question.
- formulations suitable for oral administration may include flavoring or coloring agents .
- the compounds of the present invention and their salts and solvates thereof may be employed alone or in combination with other therapeutic agents.
- the compound (s) of Formula I and the other pharmaceutically active agent (s) may be administered together or separately and, when administered separately, administration may occur simultaneously or sequentially, in any order.
- the amounts of the compound (s) of Formula I and the other pharmaceutically active agent (s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
- Example 1 Synthesis of Bis-Acridine Having a Modified Bis (4-Aminophenyl) Ether Tether
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des intercalants bis-acridines ou bis-quinolines ayant une attache bis(4-aminophényle)éther modifiée d'améliorer l'activité, la sélectivité, la solubilité et la biodisponibilité du composé anti-tumoral.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/345,728 US8975274B2 (en) | 2011-09-20 | 2012-09-18 | Compositions and methods for treating cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/236,969 US8530496B2 (en) | 2008-07-08 | 2011-09-20 | Compositions and methods for treating cancer |
US13/236,969 | 2011-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013043558A1 true WO2013043558A1 (fr) | 2013-03-28 |
Family
ID=47914785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/055847 WO2013043558A1 (fr) | 2011-09-20 | 2012-09-18 | Compositions et méthodes de traitement du cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013043558A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011016952A1 (fr) * | 2009-08-04 | 2011-02-10 | Trustees Of Dartmouth College | Compositions et procédés de traitement du cancer |
-
2012
- 2012-09-18 WO PCT/US2012/055847 patent/WO2013043558A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011016952A1 (fr) * | 2009-08-04 | 2011-02-10 | Trustees Of Dartmouth College | Compositions et procédés de traitement du cancer |
Non-Patent Citations (5)
Title |
---|
NAGESHA ET AL.: "A comparative study on the interaction of acridine and synthetic bis-acridine with G-quadruplex structure", J. BIOCHEM. BIOPHYS. METHODS, vol. 57, 2003, pages 65 - 74 * |
PALIT ET AL.: "Phase transfer catalyzed synthesis of bis-quinolines: Antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2009, pages 845E853 * |
SEBESTIK ET AL.: "Solid-phase synthesis of head and tail bis-acridinylated peptides", TETRAHEDRON I LETTERS, vol. 45, 2004, pages 1203 - 1205, XP004484814, DOI: doi:10.1016/j.tetlet.2003.11.139 * |
STREKOWSKI ET AL.: "Bis-4-aminoquinolines: Novel Triple-Helix DNA Intercalators and Antagonists of Immunostimulatory CpG-Oligodeoxynucleotides", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, 2003, pages 1079 - 1085, XP003015264, DOI: doi:10.1016/S0968-0896(02)00525-4 * |
WANG ET AL.: "Linker-modified triamine-linked acridine dimers: Synthesis and cytotoxicity properties in vitro and in vivo", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15, 2007, pages 735 - 748, XP005882794, DOI: doi:10.1016/j.bmc.2006.10.054 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11530219B2 (en) | Ligands to cereblon (CRBN) | |
KR20200100717A (ko) | 비아릴 유도체, 이의 합성법과 그 약학적 용법 | |
US20190210997A1 (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | |
TWI781938B (zh) | 苯基丙醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
JP6621329B2 (ja) | 新規化合物、それらの合成及びそれらの使用 | |
Brana et al. | Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz [de, h] isoquinoline-1, 3-diones | |
US20220177466A1 (en) | Degraders of kelch-like ech-associated protein 1 (keap1) | |
CN113164475A (zh) | Dyrk1a的大环抑制剂 | |
EP3856190A1 (fr) | Dégradation de fak ou fak et alk par conjugaison d'inhibiteurs de fak et d'alk avec des ligands de ligase e3 et procédés d'utilisation | |
CN113527293A (zh) | Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途 | |
WO2023114460A1 (fr) | Agents de dégradation de bcl6 et leurs utilisations | |
BR112015022849B1 (pt) | Sais de adição de base de nitroxolina, usos e processo para preparação dos mesmos, bem como seu cristal, composição farmacêutica e processo para preparação da mesma | |
CN109879934A (zh) | 一种苯基丙酰胺类衍生物的盐及其制备方法 | |
TW202144369A (zh) | 海鞘素類衍生物及其製備方法與醫藥用途 | |
US8530496B2 (en) | Compositions and methods for treating cancer | |
US8975274B2 (en) | Compositions and methods for treating cancer | |
CA2485494C (fr) | Carboxamides polycycliques anti-tumorales | |
TWI773118B (zh) | 四氫異喹啉衍生物 | |
WO2013043558A1 (fr) | Compositions et méthodes de traitement du cancer | |
US8765781B2 (en) | Bis-carbazole DNA intercalating agents for antitumor therapy | |
WO2007010044A1 (fr) | Derives de 3-indolyl-methylene a effet cytostatique | |
CN108017639B (zh) | Ido抑制剂及其制备方法和应用 | |
CN107235960B (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
US20200038371A1 (en) | Compound having anticancer activity and preparation method and application | |
US20230149551A1 (en) | Arginine methyltransferase 5 (prmt5) degraders and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12832940 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14345728 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12832940 Country of ref document: EP Kind code of ref document: A1 |